Navigation Links
Talecris Biotherapeutics Announces Fourth Quarter and Full Year 2010 Results
Date:2/23/2011

RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2011 /PRNewswire/ -- Talecris Biotherapeutics Holdings Corp. ("Talecris") (Nasdaq: TLCR) today announced its financial results for the three and twelve months ended December 31, 2010 and filed its Form 10-K with the U.S. Securities and Exchange Commission (SEC).

Fourth quarter 2010 net revenue increased by $20.7 million or 5.3% to $410.8 million from $390.1 million in the fourth quarter of 2009.  Higher revenues from Talecris' principal products Gamunex-C®/Gamunex®  Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV) and Prolastin® Alpha-1 Proteinase Inhibitor (Human) (Prolastin, Prolastin A1PI, Prolastin-C A1PI) as well as Thrombate® III Antithrombin III (Human) in the fourth quarter of 2010 were partially offset by lower sales of albumin, hyperimmunes and contract manufacturing compared to the fourth quarter of 2009.  Fourth quarter 2010 gross margin was 41.2% compared to 39.2% in the fourth quarter of 2009.  Fourth quarter 2010 income from operations was $68.5 million versus $57.4 million for the fourth quarter of 2009, a 19.3% increase.  Net income was $17.1 million for the fourth quarter of 2010, an increase of $15.7 million compared to net income of $1.4 million for the fourth quarter of 2009.  Diluted earnings per share were $0.13 in the fourth quarter of 2010, including an after-tax charge of $6.3 million ($0.05 per diluted share) for costs associated with Talecris' definitive merger agreement with Grifols S.A. and Grifols, Inc. (Grifols) as well as an after-tax charge of $26.6 million ($0.20 per diluted share) as the result of the Plasma Centers of America, LLC (PCA) jury verdict and related interest expense, compared to diluted earnings per share of $0.01 (pro forma diluted EPS of $0.00) for the fourth quarter of 2009. Talecris' fourth quarter 2009
'/>"/>

SOURCE Talecris Biotherapeutics Holdings Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
2. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
3. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
4. Siemens/Talecris Win Best Partnership in the Outsourcing Excellence Awards
5. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
6. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
7. Talecris Added to NASDAQ Biotechnology Index
8. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
9. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
10. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
11. Talecris Biotherapeutics Announces Premerger HSR Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Calif. , July 25, 2014 Amgen ... of Directors today declared a $0.61 per share dividend ... be paid on Sept. 5, 2014, to all stockholders ... Aug. 14, 2014.  About Amgen Amgen ... patients suffering from serious illnesses by discovering, developing, manufacturing ...
(Date:7/25/2014)... WABC Radio show out of New York City, ... will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, Robert ... pets. Dr. Harman first visited the show in November ... pets suffering from osteoarthritis and other degenerative diseases, as well ... , Young has invited Dr. Harman back to dial down ...
(Date:7/25/2014)... 25, 2014 At the request of ... a 60-day extension for the public comment period (Docket ... for Model Aircraft established by Congress as part of ... 60-day extension establishes the new deadline for comments as ... of Transportation/FAA notice published in the Federal Register on ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3FAA Grants Comment Extension at the Request of AMA 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... FRANCISCO, March 7, 2012  More than 1,100 leaders from ... Francisco for the two-day conference CALBIO2012: Driven by Patients ... patient access to new treatments through partnering and collaborative ... BIOCOM are organizing a statewide meeting for California,s life ...
... Palatin Technologies, Inc. (NYSE Amex: PTN ) ... ROTH OC Growth Stock Conference on Tuesday, March 13, 2012, ... at the Ritz Carlton Laguna Niguel in Dana Point, CA. ... Officer of Palatin Technologies, will provide an update on Palatin,s ...
...  Synthetic Biologics, Inc.  (NYSE Amex: SYN ), ... medicines for serious illnesses, announced today that Jeff Riley, ... ROTH Capital Partners 24th Annual Growth Stock Conference. The ... Ritz Carlton in Dana Point, CA. Mr. Riley will ...
Cached Biology Technology:First Statewide Biotech Meeting Focuses on Patient Access, Innovation 2Synthetic Biologics to Present at ROTH Annual Growth Stock Conference 2
(Date:7/28/2014)... Biologically Inspired Engineering at Harvard University today announced ... by a newly formed private company to accelerate ... products. The announcement follows a worldwide ... (OTD) and the start-up Emulate Inc., relating to ... platform. , "This is a big win ...
(Date:7/27/2014)... largest prevalence studies to date, researchers from the U.K. ... the hepatitis C virus (HCV). Findings published in Hepatology, ... of Liver Diseases, indicate that genotype 1 is the ... of which one-third reside in East Asia. Genotype 3, ... most prevalent, followed by genotypes 2, 4, 6, and ...
(Date:7/27/2014)... single computer cannot always find the solution a user ... cluster of computers that analyze a massive data set ... history to present you with targeted ads, and how ... movie. But big data is about more than just ... are generating unprecedented quantities of information. That data may ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Hepatitis C virus genotype 1 is most prevalent worldwide 2New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5
... San Diego have identified a potential red tide killer. ... accumulate rapidly in dense concentrations have been on the ... dollars in worldwide losses to fisheries and beach tourism ... referred to as harmful algal blooms, remain unpredictable in ...
... Using classroom, hands-on activities can help instructors to ... Despite its importance, the diversity in soil microbes ... natural resource classrooms composed primarily of undergraduates who ... the candy comes into play. , Stephanie ...
... at City of Hope and the California Department of ... detect botulinum neurotoxin. The toxin is one of the ... and is considered a major potential bioterrorism threat agent. ... the online journal PLoS ONE ( http://www.plosone.org/doi/pone.0002041 ). ...
Cached Biology News:Scripps Oceanography Research pegs ID of red tide killer 2Scripps Oceanography Research pegs ID of red tide killer 3The sweet world of soil microbiology 2Researchers develop new ultrasensitive assay to detect most poisonous substance known 2
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,448-8) or ...
Biology Products: